
Celgene has opened new UK headquarters in London as its haematology-based business expands. The firm says it has decided to …
Earlier this year we reported on progress in the consolidation of the UK medicines legislation and that the Medicines and …
The European Medicines Agency has accepted Pfizer’s arthritis drug tofacitinib for review.Tofacitinib is a novel, oral JAK inhibitor being studied …
The European Medicines Agency’s new executive director Guido Rasi has appointed Andreas Pott as deputy executive director. Pott’s appointment follows …

The FDA has pulled Avastin’s breast cancer licence in the US after the drug failed to prove its safety and …

Dipankar Bhattacharjee has been promoted to vice president of UK and Teva Northern Europe. Teva said that as part of …
Chinese outsourcing services specialist WuXi Pharmatech reported a 24% increase in third-quarter sales to $104 million thanks to a robust …
Workers at Novartis’ Nyon facility in Switzerland carried out a strike to protest the closure of the plant, but called …
AstraZeneca’s thyroid cancer pill Caprelsa has taken a step closer to European approval after being recommended by the CHMP.Caprelsa (vandetanib) …

AstraZeneca has thrown more light on the pending closure of its UK R&D site in Charnwood, saying that 90% of …
One of the world’s first stem cell trials has been put on hold due to ‘uncertain economic conditions’.Geron, the firm undertaking …
Bayer is expecting sales in Asia to grow by €11 billion over the next four years, with over half of …
The European Commission and the European pharma industry have unveiled plans to accelerate the discovery and development of new antibiotics. …

Pharmaceutical consultancy firm The MSI Consultancy has appointed Jeremy Poland as a Graduate Analyst in its Marketing Sciences division. Jeremy …

NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …

Life Healthcare Communications has made four new appointments, adding to its client service, creative and digital teams. Vicki Marsh joins …
GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …
The potential benefits of standardisation in the conduct of an increasingly global clinical research effort are enormous. The promise of …